Halo Collective Plans to Expand Retail Space after Record Sales

Nov.23.2022
Halo Collective Plans to Expand Retail Space after Record Sales
Halo Collective reports highest sales quarter and plans to expand Budega retail stores, aiming for seven more locations in the US by 2023.

During this quarter, Halo Collective experienced its highest reported sales and continues to plan expansion with the successful opening of its first two Budega retail stores. The opening of the third supermarket store has made significant progress.


After reviewing its current operations, the company is actively seeking additional retail space and licenses in the United States, with a goal of securing up to seven locations by the end of 2023. Retail stores represent a valuable resource for sales and customer data, as they allow for vertical integration and offer a range of cannabis-related products, including food, pre-rolls, e-cigarettes, flowers, tinctures, creams, and more.


The company has successfully acquired three locations in the California area, including Westwood, NoHo, and now Hollywood, and plans to open seven more stores next year. Since its opening in early March of this year, the NoHo store has continued to grow with steady increases in revenue, offering unique promotional events to drive consumer traffic while maintaining a loyal and consistent customer base. In October of last year, the company implemented innovative changes to increase the stores' net profit. All retail locations promote their own products, including the top-selling Budega and Hush flower brands.


Westwood has experienced rapid growth over the past six months, with monthly revenues nearly doubling and peaking in sales in October of last year. Sales in the third quarter increased by 94% compared to the second quarter, and the company anticipates fourth quarter sales in Westwood to be based on October's sales figures. The pharmacy is conveniently located between Westwood and Beverly Hills, adjacent to Santa Monica Boulevard in a high-traffic area. Westwood is also the nearest pharmacy to the tourist areas of Beverly Hills and Century City.


Budega, a retail brand in the California cannabis industry, has established its presence as a prominent player. Following positive initial evaluations, the company is continuing its expansion plans in the region next year. Budega Hollywood, the largest of its three stores, has made significant progress and is projected to generate $15 million in revenue by 2023. The company has hired a renowned contractor to oversee the store's expansion and design, and has approved renderings to move forward with the development.


Regarding Halo Collective


Halo is a company that focuses on the west coast of the United States and vertically integrates its business, covering the entire value chain from seed to sale. The company grows, extracts, manufactures, and distributes high-quality cannabis flowers, pre-rolls, vape carts, edibles, and concentrates. These products are sold under a range of brands, including Hush™, Winberry Farms™, their retail brand Budega™, as well as through a licensing agreement with FlowerShop*. Additionally, Halo has opened two dispensaries under the Budega™ brand in North Hollywood and Hollywood, with plans to open another in Hollywood in 2022.


In the non-THC space, Halo is expanding into the health and wellness categories, including CBD and functional supplements such as brain-boosting nutrition products and non-psychedelic mushrooms. Through a series of acquisitions, Halo offers products in the form of beverages (H2C Beverages), dissolvable strips (Dissolve Medical), capsules (Hushrooms™), and topical supplements (Hatshe), and plans to distribute nationally through a strategic agreement with SWAY Energy.


Halo has successfully acquired and integrated multiple companies, subsequently restructuring to create Akanda Corp. (NASDAQ stock code: AKAN), an international medical cannabis and health company in which Halo is the largest shareholder. Halo has also acquired a series of software development assets including CannPOS, Cannalift, CannaFeels, and discrete sublingual delivery technology Accudab. Halo intends to restructure these entities (including their intellectual property and patent applications) into a subsidiary named Halo Tek Inc. and complete the distribution of Halo Tek Inc. shares to registered shareholders on a date to be determined.


Statement:


This article is compiled from third-party information and is only intended for industry communication and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness and accuracy of the content. The translation of this article is only intended for communication and research within the industry.


Due to limitations in the compiler's proficiency, the translated article may not fully reflect the intended meaning of the original. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign issues and stances.


5. The copyright of the compiled information belongs to the original media and authors. If there is infringement, please contact for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
According to WNCY on August 24, 2026, some independent vape retailers in Wisconsin say they have faced significant business pressure one year after new vape regulations took effect. Johnny Vapes, a retailer operating in northeast Wisconsin, said its store count fell from seven locations to four, sales declined by about 80%, and roughly 90% of its inventory was affected. Retailers said some consumers have shifted to online purchases or traveled to neighboring Michigan to buy vape products. The case highlights how local regulations can reshape retail operations, inventory management and consumer purchasing patterns.
Aug.28
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia will place e-cigarettes and related nicotine products under its “strategic goods” framework from August 20, 2026. According to TVP World’s report published on August 19, the newly listed items include e-cigarettes, electronic smoking devices, vape liquids and nicotine salts. Individuals who illegally move these products across Russia’s customs border or its state border with other Eurasian Economic Union (EAEU) members could face up to five years in prison if shipment values exceed 100,000 rubles (about €1,000), provided all elements of a criminal offence are established.
Aug.20
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives